Note 5 - Warrants and Equity - Warrant Activity (Details)	12 Months Ended
	Dec. 31, 2025 $ / shares shares
Balance, number of shares under warrants (in shares)	312,405
Balance, number of shares under warrants (in shares)	7,602,266
Balance, warrant exercise price (in dollars per share) \| $ / shares	$ 6.43
Liability Classified Warrants [Member]
Balance, number of shares under warrants (in shares)	0
Granted, number of shares under warrants (in shares)	4,768,525
Granted, warrant exercise price (in dollars per share) \| $ / shares	$ 3.76
Granted, weighted average remaining contractual life (Year)	4 years 8 months 12 days
Adjustment from anti-dilution provisions (in shares)	1,528,326
Adjustment from anti-dilution provisions, warrant exercise price	3.9
Adjustment from anti-dilution provisions, weighted average remaining contractual life (Year)	4 years 7 months 6 days
Exercised, number of shares under warrants (in shares)	(1,376,194)
Exercised, warrant exercise price (in dollars per share) \| $ / shares	$ 3.42
Exercised, weighted average remaining contractual life (Year)	4 years 7 months 17 days
Reclassification of warrant liabilities to equity pursuant to warrant amendments, shares (in shares)	(4,906,417)
Reclassification of warrant liabilities to equity pursuant to warrant amendments, weighted average exercise price (in dollars per share) \| $ / shares	$ 3.9
Reclassification of warrant liabilities to equity pursuant to warrant amendments (Year)	4 years 8 months 8 days
Balance, number of shares under warrants (in shares)	14,240
Balance, warrant exercise price (in dollars per share) \| $ / shares	$ 3.9
Balance, weighted average remaining contractual life (Year)	4 years 7 months 6 days
Vested and Exercisable, number of shares under warrants (in shares)	14,240
Vested and Exercisable, warrant exercise price (in dollars per share) \| $ / shares	$ 3.9
Vested and Exercisable, weighted average remaining contractual life (Year)	4 years 7 months 6 days
Reclassification of warrant liabilities to equity pursuant to warrant amendments, shares (in shares)	4,906,417
Liability Classified Warrants [Member] \| Minimum [Member]
Balance, warrant exercise price (in dollars per share) \| $ / shares	$ 0
Equity Classified Warrants [Member]
Balance, number of shares under warrants (in shares)	312,405
Balance, warrant exercise price (in dollars per share) \| $ / shares	$ 47.11
Granted, number of shares under warrants (in shares)	3,485,852
Granted, warrant exercise price (in dollars per share) \| $ / shares	$ 7.79
Granted, weighted average remaining contractual life (Year)	4 years 11 months 4 days
Exercised, number of shares under warrants (in shares)	(1,111,909)
Exercised, warrant exercise price (in dollars per share) \| $ / shares	$ 19.4
Exercised, weighted average remaining contractual life (Year)	5 years 7 months 28 days
Reclassification of warrant liabilities to equity pursuant to warrant amendments, shares (in shares)	(4,906,417)
Reclassification of warrant liabilities to equity pursuant to warrant amendments, weighted average exercise price (in dollars per share) \| $ / shares	$ 3.9
Reclassification of warrant liabilities to equity pursuant to warrant amendments (Year)	4 years 8 months 8 days
Balance, number of shares under warrants (in shares)	7,588,026
Balance, warrant exercise price (in dollars per share) \| $ / shares	$ 4.34
Balance, weighted average remaining contractual life (Year)	4 years 9 months 14 days
Vested and Exercisable, number of shares under warrants (in shares)	4,943,149
Vested and Exercisable, warrant exercise price (in dollars per share) \| $ / shares	$ 6.43
Vested and Exercisable, weighted average remaining contractual life (Year)	4 years 8 months 8 days
Balance, weighted average remaining contractual life (Year)	7 years 10 months 6 days
Expired warrants, number of shares under warrants (in shares)	(4,739)
Expired warrants, warrant exercise price (in dollars per share) \| $ / shares	$ 1,365.85
Expired warrants, weighted average remaining contractual life (Year)	4 years 1 month 6 days
Reclassification of warrant liabilities to equity pursuant to warrant amendments, shares (in shares)	4,906,417

Moleculin Biotech, Inc. 10-K